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Abstract
PSA-RP2 is a variant transcript expressed from the PSA gene
that is conserved in gorillas, chimpanzees and humans sug-
gesting a particular relevance for this transcript in these
primates. We demonstrated by qRT-PCR that PSA-RP2 is
upregulated in prostate cancer compared with benign pro-
static hyperplasia tissues. The PSA-RP2 protein was not
detected in seminal fluid and was cytoplasmically localised
but not secreted from LNCaP or transfected PC3 prostate
cells, despite secretion from transfected Cos-7 and HEK293
kidney cell lines. PSA-RP2-transfected PC3 cells showed
slightly decreased proliferation and increased migration
towards PC3-conditioned medium that could suggest a func-
tional role in prostate cancer.
Keywords: alternative splicing; biomarker; kallikrein-
related peptidase; prostate-specific antigen (PSA).
Alternative splicing of human genes is an important contrib-
utor to the diversity of proteins expressed in the cell. The
kallikrein-related peptidase (KLK) family of serine proteases
consists of 15 genes, each of which produces more than one
mRNA transcript (Clements et al., 2004; Kurlender et al.,
2005; Tan et al., 2006). Over 80 mRNA transcripts arise
from the kallikrein-related peptidase family (Kurlender et al.,
2005), but on the whole the variant transcripts have been
poorly characterised and their roles within the cell are largely
unknown. Across the KLK gene family, exon skipping is the
most common event that gives rise to alternative transcripts
(Kurlender et al., 2005). Intron retention is also a frequent
event, and usually involves the retention of intron 3 (Kur-
lender et al., 2005) with only two reported cases of intron 1
retention (David et al., 2002). In the case of the PSA (KLK3)
gene, analysis of the sequences surrounding intron 3 sug-
gested suboptimal splice sites (Heuze-Vourc’h et al., 2003).
The vast majority of variant KLK transcripts encode trun-
cated proteins (Kurlender et al., 2005), and as most of these
lack one or more residues of the catalytic triad they are not
expected to possess serine protease activity (Tan et al., 2006).
This does not preclude novel non-proteolytic roles for these
variant KLK proteins, as previously described for PSA in
stimulating the release of reactive oxygen species (Sun et al.,
2001) and anti-angiogenesis (Fortier et al., 2003).
Prostate-specific antigen (PSA or KLK3) is the biomarker
used in diagnosis and monitoring of prostate cancer. It is
secreted by prostate epithelial cells into the prostate gland
and subsequently into seminal fluid where it plays a major
role in the degradation of semenogelin (Lundwall and Bratt-
sand, 2008). Although an excellent marker for tumour recur-
rence, the PSA blood test lacks specificity and, furthermore,
in prostate cancer, does not discriminate aggressive cancers
from more slow-growing disease; therefore, improved diag-
nostic and prognostic markers are needed (Steuber et al.,
2008; Stephan et al., 2009). Several variant transcripts from
the PSA gene have been identified, including two transcripts,
PSA-RP2 and PSA-424 (Riegman et al., 1988; Heuze-
Vourc’h et al., 2001), which arise owing to retention of intron
3 and differ only by the length of their 39UTR. The full-
length PSA protein is 261 residues in length. The protein
expressed from both the PSA-RP2 and PSA-424 transcripts
is 180 residues in length (Figure 1A), in which the first 164
residues are identical to PSA, followed by a unique 16 res-
idue sequence before a premature stop codon (GenBank
CAC41631; Figure 1B). Expression of the PSA-RP2 pro-
tein has been confirmed previously in prostatic tissue
(Heuze-Vourc’h et al., 2001, 2003). As PSA-RP2 lacks the
serine residue of the catalytic triad (Figure 1A), it is not
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Figure 1 Expression of PSA-RP2 in prostatic tissues.
(A) Structure of PSA and PSA-RP2 proteins. The positions of the catalytic triad of histidine (His), aspartate (Asp) and serine (Ser) residues
are indicated on the PSA diagram. Only the histidine and aspartate residues of the catalytic triad are present in PSA-RP2. The 17-residue
signal peptide (‘SP’) and 7-residue pro-peptide (‘pro’, shaded) are indicated on the diagram. Residue numbering is from the start of the
preproprotein. (B) Partial alignment of PSA and PSA-RP2 protein sequences. Residues 1–164 of PSA (top) and PSA-RP2 (bottom) are
identical. Residues 165–180 of the PSA-RP2 protein (bold underline) are derived from the retained intron 3 sequence and are unique to
PSA-RP2. (C) PSA-RP2 mRNA expression is higher in prostate cancer than BPH. Total RNA was extracted using Tri-Reagent (Sigma-
Aldrich, Castle Hill, NSW, Australia) from prostate tissues from men with prostate cancer or BPH who gave informed consent following
the approval of the relevant institutional human ethics committees. RNA was treated with DNase I (Roche Applied Science, Castle Hill,
NSW, Australia) before reverse transcription using Superscript II (Invitrogen, Mulgrave, VIC, Australia) and an oligo-dT primer. Real-time
RT-PCR was performed using SYBR Green I (Applied Biosystems, Victoria, Australia) and primers for PSA-RP2 (forward: 59-GAG TGT
ACG CCT GGG CCA GAT-39; reverse: 59-CTG AGG GTG AAC TTG CGC ACA C-39). Relative levels of gene expression were normalised
to b2-microglobulin. Each sample was amplified twice in duplicate. Statistical analysis was performed with the Student t-test. Data is shown
as average "standard error and demonstrates that PSA-RP2 mRNA expression is significantly higher in prostate cancer (19 patients)
compared with BPH (14 patients) (p-0.05). (D) PSA-RP2 is not secreted into seminal fluid. Western blot analysis of LNCaP prostate cancer
cell lysate (dihydrotestosterone-treated) and seminal fluid (10 ml – PSA Western; 20 ml – PSA-RP2 Western) run on a 12% SDS-PAGE
under reducing conditions. The polyclonal PSA antibody was from Dako Australia (Campbellfield, VIC, Australia). The polyclonal antibody
to PSA-RP2 was raised in rabbits (IMVS, Adelaide, Australia) against a synthetic peptide (CTPGPDGAAGSPDAWV) corresponding to the
unique C-terminal 16 residues of PSA-RP2 (Figure 1A) conjugated to keyhole limpet hemocyanin (Mimotopes, Melbourne, Australia). The
antiserum was affinity-purified using the immunising peptide conjugated to thiopropyl sepharose (Mimotopes). Despite high levels of PSA,
no PSA-RP2 was detected in the seminal fluid sample.
expected to retain any of the catalytic activities of PSA;
however, this would not preclude a potential non-proteolytic
function and/or its possible utility as a biomarker.
The use of additional biomarkers and other parameters,
combined with serum PSA in multivariate models, could
increase the specificity of prostate cancer detection and
reduce unnecessary biopsies (Sardana et al., 2008; Stephan
et al., 2009). For example, %free PSA has been reported to
decrease the false positive rate by helping to distinguish the
contribution to total PSA from non-cancerous prostatic con-
ditions such as benign prostatic hyperplasia (BPH) (Stenman
et al., 1999) and other PSA transcriptionally regulated
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(pro-PSA) and post-translationally generated variants (B-
PSA) have been mooted as potentially useful adjunct bio-
markers (Linton et al., 2003; Khan et al., 2004; Mikolajczyk
et al., 2004).
To determine its potential relevance to prostate cancer, we
first assessed PSA-RP2 gene expression in patient tissues.
RNA obtained from prostate cancer (19 patients) and BPH
(14 patients) tissues was analysed by quantitative real-time
PCR for levels of PSA-RP2 expression. This demonstrated
that PSA-RP2 mRNA was significantly overexpressed in
prostate cancer versus BPH (p-0.05; Figure 1C). No signif-
icant correlation of PSA-RP2 expression with tumour grade
was found in this small cohort (data not shown). We per-
formed further characterisation of this protein to determine
its role in prostate cancer cells and as a possible biomarker
for prostate cancer. A specific rabbit polyclonal PSA-RP2
antibody was raised against a synthetic peptide correspond-
ing to the 16-residue C-terminal sequence unique to PSA-
RP2 (CTPGPDGAAGSPDAWV) (Figure 1B). Although this
antibody could detect PSA-RP2 in LNCaP prostate cancer
cell lysates, no secretion of PSA-RP2 into seminal fluid
could be detected, despite high levels of PSA (Figure 1D).
This was unexpected as PSA-RP2 retains the N-terminal sig-
nal peptide required for secretion of PSA. In addition, pre-
vious results (Heuze-Vourc’h et al., 2001) had demonstrated
secretion of recombinant PSA-RP2 from Cos-7 cells. To
resolve this, we transfected PSA-RP2 into a range of cell
lines and showed that it was localised to the cytoplasm as
would be expected for a secreted protein (Figure 2A). We
also confirmed that it was secreted from Cos-7 cells and an
additional kidney cell line (HEK293) but not from two
prostatic cell lines (endogenous LNCaP, transfected PC3;
Figure 2B). Glycosylation of PSA-RP2 (results not shown)
leads to an increased molecular mass which probably
accounts for the size difference between the secreted and
intracellular forms in Cos-7 and HEK293 cells. In prostate
cancer tissue sections (Figure 2C), some cancerous glands
stained more strongly than non-cancerous, benign-appearing
regions of the same tissue. Overall, however, on scoring of
the staining across four sections no consistent difference in
PSA-RP2 intensity was apparent between benign and can-
cerous regions. In addition, some PSA-RP2 protein appeared
to be localised in the nucleus, as has been reported for KLK4
(Dong et al., 2005).
From these findings it appears that PSA-RP2 is neither
secreted by cultured prostatic cells nor into seminal fluid,
although further studies would be necessary to investigate
PSA-RP2 levels further in seminal fluid samples and in
serum. Although PSA-RP2 is identical to PSA at the N-ter-
minus, and therefore contains the signal peptide required for
secretion, the C-terminus is truncated which could alter the
folding of the protein and impede its secretion. The fact that
the protein is secreted from neither LNCaP nor PC3 cells
most probably reflects differences in secretory organelles and
efficiencies, perhaps related to glycosylation events, between
renal and prostatic cells. Unless there is significant basal
leakage into serum, it is unlikely that PSA-RP2 would be
found in the circulation, and thus the likelihood that it could be
used as a serum biomarker is limited. Nevertheless, it could
still serve as a useful discriminator for immunohistochemical
screening of biopsy samples, although confirmatory studies
would be required to evaluate this potential application.
Although it appears that PSA-RP2 is unlikely to have util-
ity as a secreted biomarker, we also aimed to address whether
the upregulation of PSA-RP2 in prostate cancer could play
a role in initiation or progression of prostate cancer. To this
end, we expressed PSA-RP2 in PC3 prostate cancer cells and
performed proliferation and migration assays. PSA-RP2 was
not expected to be a catalytically active serine protease,
owing to truncation of the protein before the serine residue
of the catalytic triad. However, functions for PSA that are
unrelated to its catalytic activity have been reported previ-
ously (Sun et al., 2001; Fortier et al., 2003) and the large
number of variant transcripts (over 80 identified transcripts;
Kurlender et al., 2005; Tan et al., 2006) identified for the
family of kallikrein-related peptidases raises questions about
their roles within cells. As PC3 cells lack expression of PSA-
RP2, we used this cell line to study the effects of PSA-RP2
expression in prostatic cells. PC3 cells were transfected with
a construct encoding PSA-RP2, or vector only, and stably
transfected clones were selected. Three vector-control clones
and three PSA-RP2-expressing clones with varying expres-
sion levels were selected for further study (Figure 3A). Over-
all, PSA-RP2-expressing clones had slightly decreased
proliferation rates at the 72-h time point (Figure 3B). Prolif-
eration rates of the individual PSA-RP2-expressing clones
are negatively correlated with levels of PSA-RP2 expression
(data not shown). As we have previously demonstrated
increased migration in PC3 cells expressing PSA (Veveris-
Lowe et al., 2005), we also investigated migration of PSA-
RP2-expressing PC3 cells across microporous membranes.
Unlike PSA, PSA-RP2 does not appear to affect migration
towards 20% foetal calf serum (FCS; Figure 3C). We addi-
tionally investigated migration towards PC3 conditioned
medium (Figure 3D) with the rationale that we had previ-
ously shown that PC3 cells can secrete chemoattractants that
induce other KLK-transfected (KLK4) PC3 cells to increase
migration (Gao et al., 2007). A statistically significant
increase in migration (p-0.01) was seen in one PSA-RP2
expressing clone (5H) compared with vector-transfected
PC3 cells; however, no significant difference was seen for
PSA-RP2-expressing clone 10D, which expressed the
highest amounts of PSA-RP2.
Although our study demonstrated limited changes to func-
tional parameters following PSA-RP2 expression, this does
not preclude the possibility that other functional effects of
PSA-RP2 or other kallikrein variants could arise through
non-catalytic interactions with active kallikrein-related pep-
tidases, their inhibitors or other cellular proteins or through
interference by the variant mRNAs at a transcriptional level.
Further research is required to investigate these parameters.
However, it is interesting to note that sequences with very high
sequence identity to PSA-RP2 (98% protein identity) exist
in gorillas and chimpanzees (Dorus et al., 2004; GenBank
numbers AAV51952, AAV51953), raising the possibility of
conservation of this transcript and further suggesting a func-
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Figure 2 Localisation of PSA-RP2.
(A) Confocal microscopy demonstrates cytoplasmic localisation of PSA-RP2 in transfected LNCaP cells. PSA-RP2 was amplified by PCR
from prostate cancer tissue cDNA (forward primer, 59-ATC GAA TTC GCA CCC GGA GAG CTG TGT-39; reverse primer, 59-GAA CTC
GAG TCA GAC CCA GGC ATC TGG-39) and cloned into pcDNA3.1/V5-His/A (Invitrogen). LNCaP cells seeded onto coverslips were
transfected with the above construct using Lipofectamine 2000. Two days post-transfection, cells were fixed with 4% paraformaldehyde,
blocked with 2% bovine serum albumin (BSA) in phosphate-buffered saline with 0.01% saponin for 30 min and then incubated overnight
with anti-V5 primary antibody (Invitrogen, 1:500 dilution) at 48C. Following incubation with a goat anti-mouse IgG AlexaFluor-488
secondary antibody together with phalloidin-568 nm (Molecular Probes, Eugene, OR, USA), coverslips were mounted using Prolong Gold
antifade mounting media (Molecular Probes). Cells were imaged using a Leica confocal microscope. (B) PSA-RP2 is secreted from cultured
kidney cells but not prostate cells. For androgen treatment, LNCaP cells were cultured in 2% charcoal-stripped FCS for 72 h and then
treated with 1 nM R1881 (dissolved in ethanol) or 0.1% ethanol control for a further 48 h. A similar pcDNA3.1 construct to that above
encoding untagged PSA-RP2 was transiently transfected into Cos-7 and HEK-293 cells and stably transfected into PC3 cells. b-Tubulin
antibody (TUB2.1, Sigma) was used as a cytoplasmic and loading control for Western blot analysis. Equivalent amounts of conditioned
medium (CM) were loaded for each sample (equal to 180 ml of original medium). Loading of whole cell lysates (WCLs) was 50 mg for
PC3/PSA-RP2 and 15 mg for other lysates. (C) Immunohistochemical analysis of PSA-RP2 expression in prostate tissues. Four archival
formalin-fixed paraffin-embedded blocks from primary prostate cancers (Gleason scores 3q4 to 4q5) were used following institutional
ethics approval. Immunohistochemistry was performed as previously described (Dong et al., 2005) using PSA-RP2 polyclonal rabbit antibody
(1:100 dilution). The EnVision peroxidase polymer detection system (Dako, Botany, Australia) was used for detection and the sections
were counterstained with Mayer’s haematoxylin and staining scored by a pathologist (H.M.S.). Panel (a), more intense PSA-RP2 staining
was seen in the cancerous (PCa) than benign (BNG) prostate gland. Panel (b), enlarged area from panel (a). Panel (c), strong staining of
PSA-RP2 is seen in prostate cancer. Panel (d), enlarged area from panel (c). Panel (e), no primary antibody as a negative control.
Bars50 mm.
tional importance. Increasingly, the kallikrein-related pepti-
dases are being associated with incidence or progression
of a number of cancers (Borgono and Diamandis 2004;
Clements et al., 2004). Thus, given the potential of other
PSA-related variant forms (Linton et al., 2003; Khan et al.,
2004; Mikolajczyk et al., 2004), a comprehensive analysis
of the functionality and biomarker potential of all KLK var-
iants is warranted. Even if such a venture did not identify
novel and useful diagnostic or prognostic markers, it could
reveal important activities involving other genes and gene
products, thus leading to a better understanding of the func-
tion of the high levels of these enzymes in prostate cancer
cells and, as a consequence, identify targets for future thera-
peutic strategies.
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Figure 3 Effect of PSA-RP2 expression on PC3 prostate cells.
(A) Confirmation of stably transfected PSA-RP2/PC3 clones by Western blot analysis. PC3 cells were transfected with empty vector or
PSA-RP2 in pcDNA3.1 (untagged). Stably transfected clones were selected with geneticin. Three clones (6, 10D, 5H), with different
levels of PSA-RP2 expression, were selected for further study. (B) Proliferation of PSA-RP2-expressing PC3 clones is significantly decreased
after 72 h. Cellular proliferation was assessed using WST-1 (Roche Applied Science) according to the manufacturer’s instructions. In four
replicate 96-well plates, 4000 cells were seeded per well. At each time point (4, 24, 48 and 72 h), one plate was assayed using WST-1.
Three vector clones (1, 4, 10C) and three PSA-RP2-expressing clones (6, 10D, 5H) were assayed, with eight replicates included on
each plate for each clone. The proliferation assays were repeated three times. Results are expressed as fold change over ts4 (average
absorbances at 24, 48 or 72 h divided by average absorbance at 4 h) to allow comparison between the clones. (C) PSA-RP2 expression
does not affect the migration of PC3 cells towards 20% FCS. Tissue culture inserts with 8 mm pores (Falcon, BD Biosciences, North Ryde,
NSW, Australia) were seeded with 2=105 cells in serum-free, phenol red-free RPMI 1640 medium containing 0.1% BSA, and allowed to
migrate towards 20% FCS as chemoattractant in the lower chamber for 24 h. Non-migrated cells remaining in the upper chamber were
removed with a cotton swab and then cells that had migrated to the underside of the chamber were fixed with cold methanol. To quantify
the number of migrated cells, cells were stained using 1% crystal violet/20% methanol, washed and dried. The remaining stain was solubilised
with 10% acetic acid and read in duplicate in a microplate reader at 595 nm. Results shown are the average of three independent experiments,
each performed in triplicate, corrected for 24-h proliferation and showing average absorbance "standard error. (D) PSA-RP2 expression
could increase the migration of PC3 cells towards PC3 conditioned medium. Migration assays were performed as above (panel C), except
that PC3-conditioned medium was used as chemoattractant. Results shown are the average of three independent experiments, each performed
in triplicate, showing average absorbance "standard error.
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